6-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine | 1375082-11-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 6-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
• 英文别名: 6-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-methylsulfanylpyrimidin-4-amine
• CAS: 1375082-11-3
• 化学式: C₁₁H₁₂ClN₅S
• 分子量: 281.769
• InChiKey: WQGFAJXFTVBENF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine 在 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 、 正丁醇 为溶剂， 生成 3-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[(1-methyl-4-piperidyl)methylamino]pyrimidin-2-yl]benzonitrile
  参考文献：
  名称：

  Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis

  摘要：

  A high-throughput screen against PknB, an essential serine-threonine protein kinase present in Mycobacterium tuberculosis (M. tuberculosis), allowed the identification of an aminoquinazoline inhibitor which was used as a starting point for SAR investigations. Although a significant improvement in enzyme affinity was achieved, the aminoquinazolines showed little or no cellular activity against M. tuberculosis. However, switching to an aminopyrimidine core scaffold and the introduction of a basic amine side chain afforded compounds with nanomolar enzyme binding affinity and micromolar minimum inhibitory concentrations against M. tuberculosis. Replacement of the pyrazole head group with pyridine then allowed equipotent compounds with improved selectivity against a human kinase panel to be obtained. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.107
• 作为产物：
  描述：

  4,6-二氯-二甲硫基嘧啶 、 3-氨基-5-环丙基-1H-吡唑 在 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以96%的产率得到6-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
  参考文献：
  名称：

  [EN] SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS
  [FR] DÉRIVÉS INDOL-5-OLE SUBSTITUÉS ET LEURS APPLICATIONS THÉRAPEUTIQUES

  摘要：

  公开号：

  WO2014071378A9

文献信息

• Substituted indol-5-ol derivatives and their therapeutical applications
  申请人：NantBioScience, Inc.

  公开号：US10160749B2

  公开（公告）日：2018-12-25

  The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.

  本发明一般涉及使用化合物治疗各种失调、疾病和病理状况，更具体地说，涉及使用取代的吲哚-5-醇衍生物调节蛋白激酶和治疗蛋白激酶介导的疾病。
• Substituted indol-5-ol derivatives and their therapeutic applications
  申请人：NantBioScience, Inc.

  公开号：US10245261B2

  公开（公告）日：2019-04-02

  The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.

  本发明一般涉及使用化合物治疗各种失调、疾病和病理状况，更具体地说，涉及使用取代的吲哚-5-醇衍生物调节蛋白激酶和治疗蛋白激酶介导的疾病。
• SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
  申请人：NantBioScience, Inc.

  公开号：EP2968332A1

  公开（公告）日：2016-01-20
• SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS
  申请人：NANT HOLDINGS IP, LLC

  公开号：US20150291564A1

  公开（公告）日：2015-10-15

  The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
• US9458137B2
  申请人：——

  公开号：US9458137B2

  公开（公告）日：2016-10-04